BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+3.83%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.15B
AUM Growth
+$6.15B
(-6.1%)
Cap. Flow
-$279M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
65
Reduced
60
Closed
12
Top Buys
| 1 |
Stryker
SYK
|
$32.9M |
| 2 |
Biohaven
BHVN
|
$30.9M |
| 3 |
UnitedHealth
UNH
|
$29M |
| 4 |
Insulet
PODD
|
$28.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$26.5M |
Top Sells
| 1 |
Insmed
INSM
|
$75M |
| 2 |
Intuitive Surgical
ISRG
|
$63.3M |
| 3 |
argenx
ARGX
|
$51.2M |
| 4 |
Boston Scientific
BSX
|
$44.6M |
| 5 |
Humana
HUM
|
$40M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Industrials | 0.05% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.02% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Privia Health
PRVA
$2.84B
| $18.4M | 0.3% |
1,059,171
| – | – |
|
77
Hologic
HOLX
$14.7B
| $18.4M | 0.3% |
247,826
-42,143
| -15% | -$3.13M |
|
78
Scholar Rock
SRRK
$3.3B
| $18M | 0.29% |
2,165,203
| – | – |
|
79
SI-BONE Inc
SIBN
$700M
| $17.9M | 0.29% |
1,387,609
+247,653
| +22% | +$3.2M |
|
80
Apellis Pharmaceuticals
APLS
$3.51B
| $17M | 0.28% |
444,404
-29,511
| -6% | -$1.13M |
|
81
Inspire Medical Systems
INSP
$2.53B
| $16.7M | 0.27% |
124,724
-92,970
| -43% | -$12.4M |
|
82
NeoGenomics
NEO
$1.06B
| $16.7M | 0.27% |
1,202,096
+256,071
| +27% | +$3.55M |
|
|
VRNA
83
Verona Pharma
VRNA
$9.18B
| $16.4M | 0.27% |
1,134,229
-5,066
| -0.4% | -$73.3K |
|
84
Legend Biotech
LEGN
$6.64B
| $16.4M | 0.27% |
369,270
+76,000
| +26% | +$3.37M |
|
85
Fate Therapeutics
FATE
$115M
| $15.9M | 0.26% |
4,839,779
| – | – |
|
86
Generation Bio
GBIO
$40.3M
| $11.1M | 0.18% |
3,918,856
+57,281
| +1% | +$162K |
|
|
87
Humana
HUM
$37.5B
| $10.6M | 0.17% |
28,440
-107,101
| -79% | -$40M |
|
88
Astrana Health
ASTH
$1.42B
| $10.2M | 0.17% |
250,617
+240,361
| +2,344% | +$9.75M |
|
89
Phreesia
PHR
$1.81B
| $9.4M | 0.15% |
443,341
| – | – |
|
90
Merck
MRK
$210B
| $9.25M | 0.15% |
74,709
-236,142
| -76% | -$29.2M |
|
91
Amgen
AMGN
$153B
| $9.23M | 0.15% |
29,528
+7,389
| +33% | +$2.31M |
|
92
AbbVie
ABBV
$374B
| $7.24M | 0.12% |
42,204
+14,611
| +53% | +$2.51M |
|
93
Glaukos
GKOS
$5.42B
| $6.62M | 0.11% |
55,926
| – | – |
|
94
Omnicell
OMCL
$1.51B
| $6.37M | 0.1% |
235,372
| – | – |
|
95
10x Genomics
TXG
$1.66B
| $6M | 0.1% |
308,311
| – | – |
|
96
AtriCure
ATRC
$1.73B
| $4.84M | 0.08% |
212,559
-234,817
| -52% | -$5.35M |
|
97
Illumina
ILMN
$15.2B
| $4.55M | 0.07% |
43,596
| – | -$127K |
|
98
BioMarin Pharmaceuticals
BMRN
$11.3B
| $4.3M | 0.07% |
52,232
-269,555
| -84% | -$22.2M |
|
99
Altimmune
ALT
$325M
| $3.99M | 0.06% |
+600,000
| New | +$3.99M |
|
|
ONC
100
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $3.66M | 0.06% |
25,629
+700
| +3% | +$99.9K |
|